News for Emergent BioSolutions Stock (EBS)

Emergent BioSolutions' COVID-19 Plasma Candidate To Be Tested As Outpatient Treatment

Benzinga • 08/25/21

Emergent BioSolutions' COVID-19 Human Immune Globulin Product Candidate to be Evaluated in NIH-Sponsored Phase 3 Clinical Trial (INSIGHT-012) of Hyperimmune Intravenous Immunoglobulin for Outpatient Treatment of COVID-19

GlobeNewsWire • 08/25/21

Emergent (EBS) Misses on Q2 Earnings, to Restart Bayview Unit

Zacks Investment Research • 07/30/21

U.S. authorities probing Emergent BioSolutions over COVID-19 vaccine issues -filing

Reuters • 07/30/21

Emergent Biosolutions' (EBS) CEO Bob Kramer on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha • 07/30/21

Emergent Biosolutions (EBS) Lags Q2 Earnings and Revenue Estimates

Zacks Investment Research • 07/30/21

Emergent BioSolutions Reports Financial Results For Second Quarter 2021

GlobeNewsWire • 07/29/21

Emergent BioSolutions Stock Higher As COVID-19 Vaccine Production To Resume At Baltimore Plant

Benzinga • 07/29/21

Emergent BioSolutions to Resume Manufacturing Covid-19 Vaccine at Bayview Facility

GlobeNewsWire • 07/29/21

Reverse the Silence Campaign Casts a National Spotlight on Overdose Risks Associated with Opioid Use

GlobeNewsWire • 07/26/21

These Companies Have Seen Large Returns From 2020 Government Investment

Benzinga • 07/23/21

Emergent BioSolutions to Release Second Quarter 2021 Financial Results and Conduct a Conference Call on July 29, 2021

GlobeNewsWire • 07/15/21

Emergent BioSolutions Faces Lawsuits Related to Vaccine Troubles

Barrons • 07/07/21

Can Emergent BioSolutions Recover From Its Recent Blunders?

The Motley Fool • 07/03/21

Faruqi & Faruqi, LLP is Investigating Emergent BioSolutions (EBS) on Behalf of its Shareholders

Newsfile Corp • 06/23/21

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 21, 2021 - EBS

Newsfile Corp • 06/21/21

Final Deadline Today: Rosen, Global Investor Counsel, Reminds Emergent BioSolutions Inc. Investors with Losses Over $100K of the Updated June 21 Deadline in Securities Class Action Due to the Recently Declared Federal Court Holiday - EBS

Newsfile Corp • 06/21/21

FINAL DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile Corp • 06/21/21

Final Deadline Monday: Rosen, A Top Ranked Law Firm, Reminds Emergent BioSolutions Inc. Investors with Losses Over $100K of the Updated June 21 Deadline in Securities Class Action Due to the Recently Declared Federal Court Holiday - EBS

Newsfile Corp • 06/20/21

DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Business Wire • 06/20/21

UPDATED DEADLINE MONDAY: ROSEN, SKILLED INVESTOR COUNSEL, Reminds Emergent BioSolutions Inc. Investors With Losses Over $100K of the Updated June 21 Deadline in Securities Class Action Due to the Recently Declared Federal Court Holiday - EBS

PRNewsWire • 06/19/21

DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile Corp • 06/18/21

Final Deadline for Investors to Actively Participate in Emergent BioSolutions Inc. (EBS) Class Action: Bronstein, Gewirtz & Grossman, LLC

Newsfile Corp • 06/18/21

EBS DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Emergent BioSolutions Inc. Investors to Secure Counsel Before Important Friday Deadline in Securities Class Action - EBS

Newsfile Corp • 06/17/21

Two Days Left to Actively Participate in Emergent BioSolutions Inc. (EBS) Class Action: Bronstein, Gewirtz & Grossman, LLC

Business Wire • 06/17/21